A pro-business POTUS with the full backing of both houses is a Perfect Storm for biotech investors.
An excess of $100 billion which has been parked overseas in BigPharma accounts is about to be unleashed in the form of premium bids for cutting edge biotech companies. This huge mergers-and-acquisitions catalyst lies around the corner as Trump will change tax laws to facilitate for U.S. companies to repatriate foreign earnings stashed abroad. In addition, Trump has targeted the FDA for reform and biotech investors know how important a receptive FDA is to industry.
The bottom line is we should see an explosion of deal activity with the Trump administration being more pro-business. We expect the next move in biotech stocks will be both long and substantial as investors realize that the “Perfect Storm†in biotech is here to stay for the next four years.
MTSL is uniquely positioned to provide you with a portfolio of biotech investments and ongoing analysis that will position you for significant profits from the upcoming “Perfect Storm†for biotech investing. Our five year performance numbers are outstanding and represent a real time stock picking ability. Our Model Portfolio is up 32.7% and the Trader’s Portfolio is up 68.42% per annum for the last five years.
Special Offer
To help you achieve these investment returns going forward, we our offering a 15 month subscription for the price of one year. In addition, you will be able to “Gift†a three month trial subscription to the biotech investor of your choice. Once you’ve subscribed, refer your friend here, and we’ll ensure they receive a 3 month trial subscription.
This offer is available through 12/31/16.
